Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report)’s share price traded down 5.1% during trading on Tuesday . The company traded as low as $2.97 and last traded at $2.97. 11,065 shares traded hands during trading, a decline of 70% from the average session volume of 36,893 shares. The stock had previously closed at $3.13.
Synaptogenix Stock Performance
The business has a 50-day moving average of $2.95 and a 200 day moving average of $3.63.
Synaptogenix (NASDAQ:SNPX – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($4.58) EPS for the quarter, missing the consensus estimate of ($1.95) by ($2.63).
Synaptogenix Company Profile
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
Read More
- Five stocks we like better than Synaptogenix
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Netflix Is On Track To Hit $1,000 By Christmas
- The Significance of Brokerage Rankings in Stock Selection
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.
